Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Soleti, G. Zuccari, C. Omini (Torino, Paullo, Italy). Aspirin inhalation treatment for COPD patients: Preliminary studies on PK and inflammatory biomarkers. Eur Respir J 2011; 38: Suppl. 55, 825

Member's Comments

No comment yet.

Related content which might interest you: Eosinophils and acute exacerbation of COPD: a potent biomarker for patients at increased risk. Preliminary reports. Source: International Congress 2018 – Clinical determinants and biomarkers of COPD Year: 2018 Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021 Utility of drug reaction assessments for inhaled therapies in patients with chronic suppurative lung diseases: results from 5 years of drug reaction assessments Source: International Congress 2018 – Studies on the mechanisms underlying airway disease Year: 2018 Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004 The effect of statin therapy in patients with chronic obstructive airway disease Source: International Congress 2015 – COPD: notable points Year: 2015 Effect of long-term treatment with fenspiride on clinical and functional status of patients with chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Monitoring of inflammatory changes in patients with bronchial asthma before and after oral corticosteroid treatment Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008 Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2007; 30: Suppl. 51, 357s Year: 2007 The interrelationship of the inflammatory markers in blood and sputum of stable COPD patients before and after treatment with inhaled steroids and N-acetylcysteine Source: Eur Respir J 2003; 22: Suppl. 45, 281s Year: 2003 Inflammatory biomarkers in the evaluation of two-year  outcomes  of omalizumab treatment in severe allergic asthma. Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 Effect of azithromycin treatment on inflammation in COPD patients Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Temporal profile and clinical utility of inflammatory markers in patients with acute exacerbation of COPD Source: Annual Congress 2008 - Structural remodelling in COPD Year: 2008 A double blind placebo controlled study to assess the effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients using novel biomarkers Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Changes in inhalation therapy after combined assessment of COPD Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction Year: 2015 Erdosteine is effective as a treatment for acute exacerbation of COPD: a systematic review of clinical trials Source: International Congress 2017 – COPD management Year: 2017 The assesment of serum TNFα levels in COPD acute exacerbation and the effects of inhaler steroids on clinical and inflammatory determinants Source: Eur Respir J 2002; 20: Suppl. 38, 312s Year: 2002 Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD Source: Eur Respir J, 55 (5) 1902119; 10.1183/13993003.02119-2019 Year: 2020 Modeling exacerbation using ozone exposure in COPD patients: CO3PD pilot study Source: International Congress 2018 – Disease exacerbations from a molecular point of view Year: 2018 Assesment of the effects of tocilizumab, adalimumab and steroid in LPS induced acute lung inflammation Source: International Congress 2016 – Airway response to infection Year: 2016 Why inflammatory phenotyping is necessary for successful drug evaluation in asthma and COPD Source: Eur Respir J 2013; 42: 891-892 Year: 2013